BAY 6755 | 439083-90-6

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: BAY 6755
• 英文名称: Bay 60-7550
• 英文别名: 2-(3,4-dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl}-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one；2-[(3,4-dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one；2-[(3,4-dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
• CAS: 439083-90-6
• 化学式: C₂₇H₃₂N₄O₄
• 分子量: 476.575
• InChiKey: MYTWFJKBZGMYCS-NQIIRXRSSA-N

物化性质

• 沸点：
  680.7±65.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO:21.65(最大浓度 mg/mL);45.43(最大浓度 mM)乙醇:10.0(最大浓度 mg/mL);20.98(最大浓度 mM)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  5

制备方法与用途

生物活性

Bay 60-7550 是有效，选择性的 PDE2 抑制剂，Ki 值为3.8 nM。

靶点

Ki: 3.8±0.2 nM (PDE2)

体外研究

Bay 60-7550 (1 μM) increases cGMP in the neuronal cultures compared with control [F(6,14)=12.97, p<0.05 for Bay 60-7550]. Bay 60-7550 in the presence of NMDA (30 μM) results in further increases in cGMP compared with NMDA alone. The NMDA receptor antagonist MK-801 (10 μM) blocks both Bay 60-7550+NMDA-induced elevation in cGMP in neuronal cultures. Compared with untreated control cells, proliferation of PASMCs from IPAH patients is significantly reduced by BAY 60-7550 (1 μM).

体内研究

The PDE2 inhibitors Bay 60-7550 (1 mg/kg) reverses restraint stress-induced alterations in behavior, resulting in increased percentages of open-arm entries and open-arm time compared with the vehicle + restraint stress condition. In nonstressed mice, Bay 60-7550 produces a dose-dependent increase in percentages of open-arm entries and open-arm time compared with the vehicle-treated group; significant increases are observed at a dose of 3 mg/kg. In nonstressed mice, Bay 60-7550 increases, in a dose-dependent manner, the number of head-dips and time spent head-dipping, compared with vehicle-treated mice; significant increases are observed at doses of 1 and 3 mg/kg.

反应信息

• 作为产物：
  描述：

  BAY 60-7550 生成 BAY 6755 、 2-(3,4-二甲氧基苄基)-7-((2S,3S)-2-羟基-6-苯基己-3-基)-5-甲基咪唑
  参考文献：
  名称：

  [EN] PRODUCTS AND PHARMACEUTICAL COMPOSITIONS
  [FR] PRODUITS ET COMPOSITIONS PHARMACEUTIQUES

  摘要：

  本发明涉及一种包含PDE1抑制剂和PDE2抑制剂的产品，以自由或盐形式存在，包括它们的药物组合物以及它们作为治疗cAMP和/或cGMP相关疾病的药物的用途。

  公开号：

  WO2015106032A1

文献信息

• Substituted imidazotriazinones
  申请人：——

  公开号：US20020198377A1

  公开（公告）日：2002-12-26

  The present invention relates to new substituted imidazotriazinones, processes for their preparation, and their use for the production of medicaments, in particular for improving perception, concentration power, learning power and/or memory power.

  本发明涉及新的取代咪唑三嗪酮化合物，其制备方法，以及它们用于生产药物，特别是用于改善感知能力、集中力、学习能力和/或记忆力的用途。
• Products and pharmaceutical compositions
  申请人：Intra-Cellular Therapies, Inc.

  公开号：US09849132B2

  公开（公告）日：2017-12-26

  The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.

  本发明涉及一种包含PDE1抑制剂和PDE2抑制剂的产品，以自由形式或盐形式存在，包括它们的药物组合物并将其用作治疗cAMP和/或cGMP相关疾病的药物。
• Treatment of tachycardia
  申请人：OSLO UNIVERSITY HOSPITAL HF

  公开号：US11419874B2

  公开（公告）日：2022-08-23

  The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.

  本发明提供了用于治疗心动过速或心动过速性心律失常的选择性 PDE2 抑制剂化合物：心房性心动过速、心房颤动、心房扑动、阵发性室上性心动过速、室性早搏 （PVC）、心室颤动和室性心动过速，可单独使用或与其它常规心血管药物（如 β-受体阻滞剂）联合使用。如β-受体阻滞剂。特别是，本发明提供的化合物是选择性 PDE2 抑制剂，可用于治疗心力衰竭、CPVT 或长 QT 综合征患者的室性心动过速或有此风险的患者的室性心动过速。
• Composition comprising a pulmonary surfactant and a pde2 inhibitor
  申请人：Wollin Stefan-Lutz

  公开号：US20060229242A1

  公开（公告）日：2006-10-12

  The invention relates to the combined administration of a pulmonary surfactant and a PDE2 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 2 (PDE2) activity is detrimental.

  本发明涉及肺表面活性物质和PDE2抑制剂的联合用药，用于治疗肺表面活性物质功能失调和/或磷酸二酯酶2（PDE2）活性低下的疾病。
• NEUE SUBSTITUIERTE IMIDAZOTRIAZINONE ALS PDE II-INHIBITOREN
  申请人：Bayer HealthCare AG

  公开号：EP1347978B1

  公开（公告）日：2005-08-31